Patient-partnered drug discovery: vision or reality?

pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Astellas, about why partnering with patients is the corners

Astellas buys gene therapy company for $3bn

Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery eff

AZ preps for US filing of kidney disease anaemia drug

AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia from chronic kidney disease (CKD), after supportive phase 3 results.

Astellas cuts $795m deal with Pandion for type 1 diabetes dr...

Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival dr

Astellas maintains lead over Daiichi Sankyo with CHMP okay f...